Bispecific Antibodies for use in treatment of NLRC4-GOF inflammasomapathy
AssigneeNovartis AG
InventorsGuido JUNGE, Michael KIFFE, Jiri KOVARIK, Richard STEIN, Frank WALDRON-LYNCH
Life of this patent
Estimating the term…
Abstract
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This invention also relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of AIFEC in a subject in need thereof.
Claims33
A method for the treatment or prevention of an NLRC4 inflammasomopathy in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a bispecific antibody, wherein the antibody comprises
- a. a first part which is an immunoglobulin with a first variable light chain of (VL1) and a first variable heavy chain (VH1), that binds specifically to a IL1β, and a first constant heavy chain (CH1) with a hetero-dimerization modification, and
- b. a second part which is an immunoglobulin with a second variable light chain (VL2) and a second variable heavy chain (VH2), that binds specifically to IL-18 and a second constant heavy chain (CH2) with a hetero-dimerization modification which is complementary to the hetero-dimerization modification of the first constant heavy chain.
(canceled)
-26. (canceled)
-43. (canceled)
A method of reducing the serum C-reactive protein (CRP) level in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a bispecific antibody comprising
- a. a first immunoglobulin VH1 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 85,
- b. a first immunoglobulin VL1 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 101,
- c. a second immunoglobulin VH2 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 53, and
- d. a second immunoglobulin VL2 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 69.
A method of reducing serum ferritin level in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a bispecific antibody comprising
- a. a first immunoglobulin VH1 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 85,
- b. a first immunoglobulin VL1 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 101,
- c. a second immunoglobulin VH2 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 53, and
- d. a second immunoglobulin VL2 domain of the bispecific antibody comprises the amino acid sequence SEQ ID NO:
- 69.
Dependencies are inferred from the claim text.